
FDA approves pz-cel for recessive dystrophic epidermolysis bullosa
On April 25, 2025, the FDA approved prademagene zamikeracel (Zevaskyn; Abeona Therapeutics) (pz-cel), as the first and only autologous, gene-modified cell therapy for adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), …